BioSpace News Archive

October may be National Breast Cancer Awareness month, but at Margaret West Comprehensive Breast Center, our breast team is working every day of every month to identify, prevent, and treat breast cancer.

ELITechGroup Inc., recognized worldwide for proven performance and reliability of clinical laboratory diagnostic equipment and reagents, and recipient of SelectScience’s Clinical Company of the Year for 2019, announces that it will be managing sales, customer support, applications support, service and supply chain directly in Canada.

Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today presented a poster showing preclinical data supporting HPN328 as a treatment for small cell lung cancer (SCLC) at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics meeting in Boston.

Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing novel therapeutics for hematological and oncological diseases, announced today the presentation of preclinical data of TP-1287, an investigational oral cyclin-dependent kinase 9 (CDK9) inhibitor, in castration-sensitive and resistant prostate cancer models and TP-1454, an investigational small-molecule pyruvate kinase M2 isoform (PKM2) activator, in colorectal cancer models

Lumere has been named an 18th annual Chicago Innovation Award winner on behalf of its Category Optimization solution.

Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, as part of its commitment to finding a treatment for the symptoms of Rett syndrome, is partnering with the global Rett community to sponsor the first-ever International Rett Syndrome Burden of Illness Survey.

Deciphera Pharmaceuticals, Inc. (Nasdaq:DCPH), a clinical-stage biopharmaceutical company addressing key mechanisms of tumor drug resistance, today announced the presentation of updated results from its ongoing Phase 1 study of ripretinib, a broad-spectrum KIT and PDGFRα inhibitor, in patients with second-line through fourth-line plus GIST, as well as its Phase 1 study of DCC-3014, an oral inhibitor of CSF1R, in patients with advanced solid tumors.

Medecision, an integrated health management solutions provider that supports the health and care of more than 50 million consumers nationwide, has acquired Philadelphia-based GSI Health, a SaaS provider of workflow, engagement and compliance solutions and related services.

The FDA granted Breakthrough Device status to Med-botics, LLC, (www.med-botics.com), for its Oxalert EPOTM (Enhanced Pulse Oximeter) device.

Johnson & Johnson Consumer Inc. (the Company) today announced that 15 new tests from the same bottle of Johnson’s Baby Powder previously tested by the U.S. Food and Drug Administration (FDA) found no asbestos